Cryofocus Medtech (Shanghai) (6922) Stock Overview
A medical device company, engages in the research and development, manufacture, and sale of cryoablation minimally invasive interventional treatment technology and related medical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
6922 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cryofocus Medtech (Shanghai) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.55 |
| 52 Week High | HK$14.02 |
| 52 Week Low | HK$3.20 |
| Beta | -1.15 |
| 1 Month Change | 0.15% |
| 3 Month Change | 13.72% |
| 1 Year Change | -2.09% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.91% |
Recent News & Updates
Recent updates
Is Cryofocus Medtech (Shanghai) (HKG:6922) Using Too Much Debt?
Oct 05
Is Cryofocus Medtech (Shanghai) (HKG:6922) Using Too Much Debt?
Sep 02We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate
Jan 10Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans
Oct 03Companies Like Cryofocus Medtech (Shanghai) (HKG:6922) Are In A Position To Invest In Growth
May 30Shareholder Returns
| 6922 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -2.5% | 1.6% | 1.8% |
| 1Y | -2.1% | 64.6% | 39.6% |
Return vs Industry: 6922 underperformed the Hong Kong Medical Equipment industry which returned 64.6% over the past year.
Return vs Market: 6922 underperformed the Hong Kong Market which returned 39.6% over the past year.
Price Volatility
| 6922 volatility | |
|---|---|
| 6922 Average Weekly Movement | 9.5% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 6922 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6922's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 180 | Jun Zhu | www.cryofocus.com |
Cryofocus Medtech (Shanghai) Co., Ltd., a medical device company, engages in the research and development, manufacture, and sale of cryoablation minimally invasive interventional treatment technology and related medical products in the People’s Republic of China. The company develops products in the areas of vascular interventional therapy for the treatment of atrial fibrillation, hypertension, and other cardiovascular diseases; and natural orifice transluminal endoscopic surgery for the treatment of urinary, respiratory, and digestive diseases. Its products include the Bladder Cryoablation System, a cryotherapy device for the treatment of non-muscle-invasive bladder cancer; the Gastric Cryoablation System, a self-developed cryoablation system indicated for performing cryoablation on gastric tumors to treat gastric cancer; the Esophageal Cryospray System, for intermediate to advanced esophagus cancer; the pulmonary nodule localization needle for CT-guided localization of lung nodules; the endoscopic clip for anastomosis for the closure of soft tissue in the digestive tract; the laparoscopic single-port multichannel access platform for laparoscopic surgery; the Atrial Fibrillation Pulsed Field Ablation System, for paroxysmal atrial fibrillation; the Anti-Gastroesophageal Reflux System, for gastroesophageal reflux disease; and other non-cryotherapy products.
Cryofocus Medtech (Shanghai) Co., Ltd. Fundamentals Summary
| 6922 fundamental statistics | |
|---|---|
| Market cap | HK$1.57b |
| Earnings (TTM) | -HK$83.14m |
| Revenue (TTM) | HK$93.15m |
Is 6922 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6922 income statement (TTM) | |
|---|---|
| Revenue | CN¥85.16m |
| Cost of Revenue | CN¥27.72m |
| Gross Profit | CN¥57.44m |
| Other Expenses | CN¥133.45m |
| Earnings | -CN¥76.01m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 67.45% |
| Net Profit Margin | -89.25% |
| Debt/Equity Ratio | 43.5% |
How did 6922 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 21:51 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cryofocus Medtech (Shanghai) Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Guoyuan Securities (HK) Ltd |
| Wen Dai | Huatai Research |